229 related articles for article (PubMed ID: 31142506)
1. Molecular Classification of Epithelial Ovarian Cancer Based on Methylation Profiling: Evidence for Survival Heterogeneity.
Bodelon C; Killian JK; Sampson JN; Anderson WF; Matsuno R; Brinton LA; Lissowska J; Anglesio MS; Bowtell DDL; Doherty JA; Ramus SJ; Talhouk A; Sherman ME; Wentzensen N
Clin Cancer Res; 2019 Oct; 25(19):5937-5946. PubMed ID: 31142506
[TBL] [Abstract][Full Text] [Related]
2. Efficient molecular subtype classification of high-grade serous ovarian cancer.
Leong HS; Galletta L; Etemadmoghadam D; George J; ; Köbel M; Ramus SJ; Bowtell D
J Pathol; 2015 Jul; 236(3):272-7. PubMed ID: 25810134
[TBL] [Abstract][Full Text] [Related]
3. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
4. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.
Karlan BY; Dering J; Walsh C; Orsulic S; Lester J; Anderson LA; Ginther CL; Fejzo M; Slamon D
Gynecol Oncol; 2014 Feb; 132(2):334-42. PubMed ID: 24368280
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic analysis of sporadic and Lynch-associated ovarian cancers reveals histology-specific patterns of DNA methylation.
Niskakoski A; Kaur S; Staff S; Renkonen-Sinisalo L; Lassus H; Järvinen HJ; Mecklin JP; Bützow R; Peltomäki P
Epigenetics; 2014 Dec; 9(12):1577-87. PubMed ID: 25625843
[TBL] [Abstract][Full Text] [Related]
6. Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome.
Wang ZC; Birkbak NJ; Culhane AC; Drapkin R; Fatima A; Tian R; Schwede M; Alsop K; Daniels KE; Piao H; Liu J; Etemadmoghadam D; Miron A; Salvesen HB; Mitchell G; DeFazio A; Quackenbush J; Berkowitz RS; Iglehart JD; Bowtell DD; ; Matulonis UA
Clin Cancer Res; 2012 Oct; 18(20):5806-15. PubMed ID: 22912389
[TBL] [Abstract][Full Text] [Related]
7. [Expression and significance of PD-1 and PD-L1 in the specimens of epithelial ovarian cancer].
Ju C; Gao JC; Zhang PX; Zhang KN; Yang S; Kang TJ; Zhao HZ; Qi WJ; Zhang QP; Kong FD; Guan HW; Shi H
Zhonghua Fu Chan Ke Za Zhi; 2020 Aug; 55(8):529-534. PubMed ID: 32854477
[No Abstract] [Full Text] [Related]
8. DNA Methylome Analyses Implicate Fallopian Tube Epithelia as the Origin for High-Grade Serous Ovarian Cancer.
Klinkebiel D; Zhang W; Akers SN; Odunsi K; Karpf AR
Mol Cancer Res; 2016 Sep; 14(9):787-94. PubMed ID: 27259716
[TBL] [Abstract][Full Text] [Related]
9. DNA methylation profiles of ovarian epithelial carcinoma tumors and cell lines.
Houshdaran S; Hawley S; Palmer C; Campan M; Olsen MN; Ventura AP; Knudsen BS; Drescher CW; Urban ND; Brown PO; Laird PW
PLoS One; 2010 Feb; 5(2):e9359. PubMed ID: 20179752
[TBL] [Abstract][Full Text] [Related]
10. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
[TBL] [Abstract][Full Text] [Related]
11. Differential analysis of ovarian and endometrial cancers identifies a methylator phenotype.
Kolbe DL; DeLoia JA; Porter-Gill P; Strange M; Petrykowska HM; Guirguis A; Krivak TC; Brody LC; Elnitski L
PLoS One; 2012; 7(3):e32941. PubMed ID: 22403726
[TBL] [Abstract][Full Text] [Related]
12. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer.
Zorn KK; Bonome T; Gangi L; Chandramouli GV; Awtrey CS; Gardner GJ; Barrett JC; Boyd J; Birrer MJ
Clin Cancer Res; 2005 Sep; 11(18):6422-30. PubMed ID: 16166416
[TBL] [Abstract][Full Text] [Related]
13. Morphologic, Immunophenotypic, and Molecular Features of Epithelial Ovarian Cancer.
Ramalingam P
Oncology (Williston Park); 2016 Feb; 30(2):166-76. PubMed ID: 26892153
[TBL] [Abstract][Full Text] [Related]
14. [Expression and promotor methylation of p73 gene in ovarian epithelial tumors].
Zhang YL; Guo XR; Shen DH; Cheng YX; Liang XD; Chen YX; Wang Y
Zhonghua Bing Li Xue Za Zhi; 2012 Jan; 41(1):33-8. PubMed ID: 22455848
[TBL] [Abstract][Full Text] [Related]
15. Gene expression profiles in three histologic types, clear-cell, endometrioid and serous ovarian carcinomas.
Pamuła-Piłat J; Rubel T; Rzepecka IK; Olbryt M; Herok R; Dansonka-Mieszkowska A; Grzybowska E; Kupryjańczyk J
J Biol Regul Homeost Agents; 2014; 28(4):659-74. PubMed ID: 25620176
[TBL] [Abstract][Full Text] [Related]
16. Distinct DNA Methylation Profiles in Ovarian Tumors: Opportunities for Novel Biomarkers.
Losi L; Fonda S; Saponaro S; Chelbi ST; Lancellotti C; Gozzi G; Alberti L; Fabbiani L; Botticelli L; Benhattar J
Int J Mol Sci; 2018 May; 19(6):. PubMed ID: 29882921
[TBL] [Abstract][Full Text] [Related]
17. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.
Tothill RW; Tinker AV; George J; Brown R; Fox SB; Lade S; Johnson DS; Trivett MK; Etemadmoghadam D; Locandro B; Traficante N; Fereday S; Hung JA; Chiew YE; Haviv I; ; Gertig D; DeFazio A; Bowtell DD
Clin Cancer Res; 2008 Aug; 14(16):5198-208. PubMed ID: 18698038
[TBL] [Abstract][Full Text] [Related]
18. Genes with bimodal expression are robust diagnostic targets that define distinct subtypes of epithelial ovarian cancer with different overall survival.
Kernagis DN; Hall AH; Datto MB
J Mol Diagn; 2012; 14(3):214-22. PubMed ID: 22490445
[TBL] [Abstract][Full Text] [Related]
19. Promoter hypermethylation contributes to frequent inactivation of a putative conditional tumor suppressor gene connective tissue growth factor in ovarian cancer.
Kikuchi R; Tsuda H; Kanai Y; Kasamatsu T; Sengoku K; Hirohashi S; Inazawa J; Imoto I
Cancer Res; 2007 Aug; 67(15):7095-105. PubMed ID: 17671176
[TBL] [Abstract][Full Text] [Related]
20. CSIOVDB: a microarray gene expression database of epithelial ovarian cancer subtype.
Tan TZ; Yang H; Ye J; Low J; Choolani M; Tan DS; Thiery JP; Huang RY
Oncotarget; 2015 Dec; 6(41):43843-52. PubMed ID: 26549805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]